Brokerages forecast that Shire PLC (NASDAQ:SHPG) will post $3.66 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Shire PLC’s earnings, with the lowest EPS estimate coming in at $3.46 and the highest estimate coming in at $3.75. Shire PLC reported earnings of $3.17 per share during the same quarter last year, which would suggest a positive year over year growth rate of 15.5%. The business is expected to announce its next quarterly earnings results before the market opens on Friday, October 27th.
On average, analysts expect that Shire PLC will report full-year earnings of $14.92 per share for the current fiscal year, with EPS estimates ranging from $14.80 to $15.04. For the next year, analysts expect that the business will report earnings of $16.03 per share, with EPS estimates ranging from $14.57 to $16.60. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Shire PLC.
Shire PLC (NASDAQ:SHPG) last posted its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%.
Several research analysts have recently commented on the stock. Cantor Fitzgerald set a $222.00 price target on shares of Shire PLC and gave the stock a “buy” rating in a research note on Saturday, July 1st. Jefferies Group LLC restated a “hold” rating and set a $206.00 price target (down previously from $216.00) on shares of Shire PLC in a research note on Wednesday, August 9th. Barclays PLC lowered shares of Shire PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 11th. Sanford C. Bernstein restated a “market perform” rating and set a $210.00 price target on shares of Shire PLC in a research note on Thursday, July 13th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $213.00 price target on shares of Shire PLC in a research note on Wednesday, October 11th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and thirteen have given a buy rating to the company’s stock. Shire PLC currently has an average rating of “Buy” and an average price target of $220.91.
Institutional investors have recently modified their holdings of the business. Oppenheimer Asset Management Inc. boosted its holdings in Shire PLC by 63.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 17,797 shares of the biopharmaceutical company’s stock valued at $2,941,000 after purchasing an additional 6,917 shares during the period. Baldwin Investment Management LLC boosted its holdings in Shire PLC by 1.4% in the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 23 shares during the period. Oak Ridge Investments LLC boosted its holdings in Shire PLC by 3.2% in the 2nd quarter. Oak Ridge Investments LLC now owns 81,011 shares of the biopharmaceutical company’s stock valued at $13,389,000 after purchasing an additional 2,528 shares during the period. Federated Investors Inc. PA boosted its holdings in Shire PLC by 38.8% in the 2nd quarter. Federated Investors Inc. PA now owns 9,153 shares of the biopharmaceutical company’s stock valued at $1,513,000 after purchasing an additional 2,560 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Shire PLC by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after purchasing an additional 13,665 shares during the period. 19.24% of the stock is owned by hedge funds and other institutional investors.
Shire PLC (NASDAQ SHPG) traded down 3.79% during trading on Friday, hitting $146.29. 2,220,913 shares of the company traded hands. The firm has a market cap of $43.57 billion, a price-to-earnings ratio of 65.45 and a beta of 1.63. Shire PLC has a one year low of $139.36 and a one year high of $192.64.
The business also recently declared a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be issued a $0.1527 dividend. This represents a yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 41.07%.
ILLEGAL ACTIVITY NOTICE: “Brokerages Anticipate Shire PLC (SHPG) to Post $3.66 Earnings Per Share” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2968938/brokerages-anticipate-shire-plc-shpg-to-post-3-66-earnings-per-share.html.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.